MicroPine™ is our proprietary microdose formulation of atropine and product candidate for the prevention of progressive myopia (nearsightedness) in children.
Moderate-to-severe myopia is associated with a change to the shape of the eye. This change can lead to significant back-of-the eye problems, including retinal detachment, choroidal and retinal atrophy, and choroidal neovascularization, all of which can lead to permanent vision loss1,2,3,4,5,6. In the US alone, there are approximately 25 million children with myopia, with up to 3 million considered to be at risk for high myopia and many times more that number in Asia6,8. We believe Eyenovia’s delivery technology is particularly well-suited for this application, potentially enabling children to easily self-administer medication while minimizing dose-related side effects. With the Optejet®’s Bluetooth capability, monitoring patient adherence ensures parents/guardians and doctors will know if their child or patient is adhering to the myopia therapy.
Disease State.
Moderate-to-severe myopia is associated with a change to the shape of the eye. This change can lead to significant back-of-the eye problems, including retinal detachment, choroidal and retinal atrophy, and choroidal neovascularization, all of which can lead to permanent vision loss 1,2,3,4,5,6. In the US alone, there are approximately 25 million children with myopia, with up to 3 million considered to be at risk for high myopia and many times more that number in Asia5,7.
Standard of Care (SOC).
Current treatment options for pediatric myopia include bifocal/multifocal glasses and contact lenses, ortho-k contact lenses, and atropine eyedrops. Atropine eyedrops have been shown to be effective in slowing the progression of myopia in children7.
Eyenovia Innovation.
MicroPine™ is our proprietary microdose formulation of atropine used in our Optejet® dispenser and product candidate for the prevention of progressive myopia (nearsightedness) in children. We believe Eyenovia’s delivery technology is particularly well-suited for this application and patient population, potentially enabling children to easily self-administer atropine medication while minimizing dose-related side effects. With the Optejet®’s Bluetooth capability, monitoring patient adherence ensures parents/guardians and doctors will know if their child or patient is adhering to the myopia therapy.
1. Vongphanit, J., Mitchell, P., & Wang, J. J. (2002). Prevalence and progression of myopic retinopathy in an older population. Ophthalmology, 109(4), 704-711.
2. Ogawa, A., & Tanaka, M. (1988). The relationship between refractive errors and retinal detachment–analysis of 1,166 retinal detachment cases. Japanese journal of ophthalmology, 32(3), 310-315.
3. Lim, R., Mitchell, P., & Cumming, R. G. (1999). Refractive associations with cataract: the blue mountains eye study. Investigative ophthalmology & visual science, 40(12), 3021-3026.
4. Mitchell, P., Houriha4. n, F., Sandbach, J., & Wang, J. J. (1999). The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology, 106(10), 2010-2015.
5. Theophanous, Christos et al. “Myopia prevalence and risk factors in children.” Clinical ophthalmology (Auckland, N.Z.) vol. 12 1581-1587. 29 Aug. 2018, doi:10.2147/OPTH.S164641
6. Chia, Audrey, et al. “Five-Year Clinical Trial on Atropine for the Treatment of Myopia” Ophthalmology, vol. 123, no. 2, 2016, pp. 391–399., doi:10.1016/j.ophtha.2015.07.004.
7. U.S. Census Bureau, Current Population Survey, Annual Social and Economic Supplement, 2019.
8. Chen et al. BMC Ophthalmology (2018) 18:159